Search - tctmd.com

Displaying 21 - 40 of 329

Sort: Relevancy | Date

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

News Conference News TCT 2024

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

Yael L. Maxwell

October 29, 2024

AI Tool Fails to Boost Outcomes in ED Triage of Suspected CV Conditions

News Conference News ESC 2024

AI Tool Fails to Boost Outcomes in ED Triage of Suspected CV Conditions

September 12, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Dropping Aspirin From Post-LAAO Regimens Seems Like a Good Idea

News Daily News

Dropping Aspirin From Post-LAAO Regimens Seems Like a Good Idea

August 27, 2024

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

News Daily News

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

June 25, 2024

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

News Daily News

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Yael L. Maxwell

June 20, 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

News Daily News

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Yael L. Maxwell

March 21, 2024

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

News Daily News

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

March 15, 2024

TCTMD’s Top 10 Most Popular Stories for January 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2024

February 01, 2024

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

News Daily News

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Yael L. Maxwell

January 10, 2024

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

News Daily News

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

Yael L. Maxwell

November 08, 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

News Daily News

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Yael L. Maxwell

October 09, 2023

Pre-TAVI PCI Linked to More Late Bleeding, With Implications for Survival

News Daily News

Pre-TAVI PCI Linked to More Late Bleeding, With Implications for Survival

September 14, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

Unguided De-escalation, Short DAPT the Best Strategies in ACS: Meta-analysis

News Daily News

Unguided De-escalation, Short DAPT the Best Strategies in ACS: Meta-analysis

Yael L. Maxwell

September 05, 2023

STOPDAPT-3: Don’t Skip Out on Aspirin Immediately After PCI

News Conference News ESC 2023

STOPDAPT-3: Don’t Skip Out on Aspirin Immediately After PCI

August 26, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.